financetom
Business
financetom
/
Business
/
Bandhan Bank Q2 profit down 5% at Rs 920 cr
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bandhan Bank Q2 profit down 5% at Rs 920 cr
Nov 2, 2020 6:16 AM

Bandhan Bank on Monday reported 5.3 percent decline in net profit at Rs 920 crore for September quarter of the current fiscal year. The bank clocked a net profit of Rs 971.80 crore in the same period of 2019-20.

Total income grew 22 percent to Rs 2,304.90 crore in July-September 2020-21 as against Rs 1,889.30 crore in the year-ago period, Bandhan Bank said in a regulatory filing. Net interest income of the Kolkata-headquartered lender jumped 25.8 percent to Rs 1,923.1 crore during the quarter while the non-interest income grew 6.1 percent to Rs 381.8 crore.

Bandhan Bank said it has reported the highest ever quarterly profit before tax at Rs 1,233 crore during the period under review. Net Interest Margin (annualised) in the quarter fell to 8 percent against 8.2 percent in year-ago period. During the quarter, the bank took accelerated additional provision on standard advances amounting to Rs 300 crore. With this provision and the additional standard assets provision that bank is carrying in micro banking portfolio, the total additional provision in books stands at Rs 2,096 crore, it said.

The bank’s gross non-performing assets fell to 1.2 percent (Rs 874 crore) of gross advances as of September 30, 2020 as against 1.8 percent (Rs 1,064.20 crore) by the year-ago same period. Net NPAs too improved to 0.4 percent (Rs 262.50 crore) from 0.6 percent (Rs 336.90 crore).

”As the moratorium ended on 31st August 2020 coupled with robust rural performance, we have seen an all-round improvement in collection, disbursement and deposits. On deposits front, we have witnessed the best ever quarter whereas on the disbursement front, we are close to pre-COVID-19 level.”

Collections have seen a steady improvement month-on-month and is expected to reach near normal in the next 90 days. We now look forward to accelerate the business in H2FY 21,” Managing Director and CEO Chandra Shekhar Ghosh said. Total Advances grew 19.4 percent to Rs 76,614.6 crore as on September 30, 2020. Total deposits increased 34.4 percent to Rs 66,127.7 crore.

Bandhan Bank stock was trading at Rs 305.50 on BSE, up 5.62 percent from the previous close.

First Published:Nov 2, 2020 3:16 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US Senate budget bill proposal keeps cuts to solar, wind incentives
US Senate budget bill proposal keeps cuts to solar, wind incentives
Jun 16, 2025
WASHINGTON (Reuters) -The U.S. Senate tax committee proposed a full phase-out of solar and wind energy tax credits by 2028 but extended the incentive to 2036 for hydropower, nuclear and geothermal energy, which are favored by President Donald Trump's administration, according to a draft bill circulated on Monday. The language released by the committee chair, Republican Senator Mike Crapo, envisages...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
Jun 16, 2025
(Reuters) -Eli Lilly ( LLY ) is in advanced talks to acquire gene editing startup Verve Therapeutics ( VERV ) for up to $1.3 billion, the Financial Times reported on Monday, citing people familiar with the matter. Reuters could not immediately verify the report. ...
BRIEF-Eli Lilly Close To Buying Gene-Editing Biotech Verve Therapeutics - FT
BRIEF-Eli Lilly Close To Buying Gene-Editing Biotech Verve Therapeutics - FT
Jun 16, 2025
June 16 (Reuters) - * ELI LILLY CLOSE TO BUYING GENE-EDITING BIOTECH VERVE THERAPEUTICS- FT * ELI LILLY IS IN ADVANCED TALKS TO BUY GENE EDITING START-UP VERVE THERAPEUTICS FOR UP TO $1.3BN - FT Source text: https://on.ft.com/4e57goZ Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved